Clinical trial
Therapy for Pediatric Hodgkin Lymphoma
NCT00145600 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00145600 |
|---|---|
| Title | Therapy for Pediatric Hodgkin Lymphoma |
| Official title | Risk-Adapted Therapy for Pediatric Hodgkin's Disease |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | 12 Week Stanford V Chemotherapy, 4 cycles of VAMP chemotherapy, 2 alternating cycles of VAMP/COP chemotherapy, 3 alternating cycles of VAMP/COP chemotherapy |
| Enrollment | 296 |
| Start date | Mar 2, 2000 |
| Primary completion | May 31, 2012 |
| Completion | Nov 5, 2021 |
| First posted | Sep 5, 2005 |
| Last update posted | Oct 20, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: